Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E. O'Dwyer, Ronan Swords, Arnon Nagler, Mary Frances McMullin, Philipp D. le Coutre, Stephen E. Langabeer, Alberto Alvarez-Iglesias, Hongxin Fan, Richard C. Woodman, Francis J. Giles, Eibhlin Conneally

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p= 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.

Original languageEnglish (US)
Pages (from-to)310-315
Number of pages6
JournalLeukemia Research
Volume38
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • CML BCR-ABL
  • Minimal residual disease
  • Molecular diagnostics
  • Nilotinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response'. Together they form a unique fingerprint.

Cite this